Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01305746 · ClinicalTrials.gov registry record · Phase 2
A Trial for Subjects With Systemic Lupus Erythematosus Who Have Completed Protocol AN-SLE3321
A Phase 2 study of Systemic Lupus Erythematosus, sponsored by Anthera Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 382
- Enrollment target
- 20
- Study locations
NCT01305746: Completed Phase 2 study of Systemic Lupus Erythematosus, sponsored by Anthera Pharmaceuticals.
NCT01305746 is a Phase 2 study of Systemic Lupus Erythematosus that has completed, run by Anthera Pharmaceuticals. The registered enrollment target is 382 participants, roughly in line with the 376-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target. The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01305746, a Phase 2 study of Systemic Lupus Erythematosus, has completed, sponsored by Anthera Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 382 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the long-term safety of A-623 in subjects with SLE.
Primary Outcome
Safety assessments such as AEs, SAEs, vital signs, ECG, clinical chemistry, hematology, and immunogenicity will be analyzed in a descriptive manner and will include infections, malignancies, injection site reactions and immunogenicity, neuropsychiatric events, and deaths
Conditions Studied
Interventions
- DRUG A-623
Study Locations (20)
Buenos Aires
- Investigator Site 404 - Caba
- Investigator Site 402 - Caba
- Investigator Site 407 - Caba
- Investigator Site 401 - Caba
California
- Investigator Site 113 - Long Beach
- Investigator Site 110 - Upland
Florida
- Investigator Site 105 - Orlando
- Investigator Site 102 - Tampa
New York
- Investigator Site 106 - Lake Success
- Investigator Site 114 - Smithtown
Oklahoma
- Investigator Site 112 - Oklahoma City
- Investigator Site 111 - Tulsa
Alabama
- Investigator Site 103 - Birmingham
Maryland
- Investigator Site 117 - Baltimore
Michigan
- Investigator Site 104 - Lansing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 382 participants |
| Start Date | 2011-04 |
| Est. Completion | 2013-10 |
| Phase | Phase 2 |
What the finished NCT01305746 record still lists
NCT01305746 is an interventional study that assigns participants to a tested intervention. The registered 382 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 376-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target.
The record links to 1 condition, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 1 intervention - of which A-623 is the first listed.
NCT01305746 names 20 study sites across 13 states, led by Buenos Aires, California, Florida.
Frequently Asked Questions
What is clinical trial NCT01305746 about?
NCT01305746 is a clinical study titled "A Trial for Subjects With Systemic Lupus Erythematosus Who Have Completed Protocol AN-SLE3321". The purpose of this study is to evaluate the long-term safety of A-623 in subjects with SLE.
What is the current status of trial NCT01305746?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 382 participants. The study started on 2011-04. Estimated completion is 2013-10.
What conditions does trial NCT01305746 study?
This clinical trial studies the following conditions: Systemic Lupus Erythematosus.
What interventions are being tested in trial NCT01305746?
The interventions under investigation include: A-623 (DRUG).
Who is sponsoring clinical trial NCT01305746?
This trial is sponsored by Anthera Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01305746 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Lupus Erythematosus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01305746's enrollment target sits among peer trials
382 21st of 99 higher than 79 of 99 other Systemic Lupus Erythematosus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Systemic Lupus Erythematosus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus
RECRUITING · Phase 2
-
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD
RECRUITING · Phase 2
-
A Study of Obexelimab in Patients With Systemic Lupus Erythematosus
RECRUITING · Phase 2
-
Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine
RECRUITING · Phase 2
-
Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases
RECRUITING · Phase 2
-
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05677490 · 382 participants · Phase 3
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
- NCT06196008 · 382 participants · NA
Telephone-based Physical Activity Coaching or Self Monitored Physical Activity to Improve Physical Function in Older Adults Who Are Undergoing Surgery for Lung Cancer and Their Caregivers
- NCT07100990 · 382 participants · Phase 3
Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX)
- NCT06056830 · 383 participants · Phase 3
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia